HomeAI · summaries
Storia in 9 fonti
Questions linger over Biogen's tau drug for Alzheimer's, as low dose reports better results
Biogen's tau-lowering diranersen slows Alzheimer's decline 26% at the lowest dose in Phase 2, but an inverse dose response and a missed endpoint cloud the data.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
- ·
apnews.com
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau.
